TSX:CRONPharmaceuticals
Assessing Cronos Group (TSX:CRON) Valuation After Mixed Returns And Improving Profitability Hopes
Why Cronos Group is on investors’ radar today
Cronos Group (TSX:CRON) has drawn investor attention after a period of mixed share performance, with gains over the past month contrasting with weaker moves in the past 3 months and year to date.
That uneven return profile, combined with ongoing losses despite annual revenue of CA$146.6 million, is prompting investors to reassess how the cannabis producer’s current valuation compares with its fundamentals.
See our latest analysis for Cronos...